Likewise, liquiritin also targeted the MAPK pathway in rheumatoid arthritis (RA) by downregulating the B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X (Bax) ratio, c-Jun N-terminal kinase (JNK), and p38 phosphorylation, as well as VEGF expression [67, 68]. The gene discussed is BCL2; the disease is rheumatoid arthritis.